Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study

BACKGROUND: This is the first study investigating the safety and efficacy of the trifunctional antibody catumaxomab administered i.p. at the end of cytoreductive surgery and postoperatively prior to standard chemotherapy in patients with primary epithelial ovarian cancer (EOC). METHODS: Patients rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Sehouli, J, Reinthaller, A, Marth, C, Reimer, D, Reimer, T, Stummvoll, W, Angleitner-Boubenizek, L, Brandt, B, Chekerov, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200087/
https://www.ncbi.nlm.nih.gov/pubmed/25225907
http://dx.doi.org/10.1038/bjc.2014.443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200087/
https://www.ncbi.nlm.nih.gov/pubmed/25225907
http://dx.doi.org/10.1038/bjc.2014.443

Ejemplares similares